Safety of Paracetamol in Osteoarthritis: What Does the Literature Say?
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Osteoarthritis (OA) is a major cause of pain and physical disability in adults, and an increasingly common disease given its associations with aging and a growing obese/overweight population. Paracetamol is widely recommended for analgesia at an early stage in the management of OA, and, although frequently prescribed, evidence suggests the efficacy of paracetamol for OA pain is low. Furthermore, there have been recent concerns over the safety profile of paracetamol, with reports of gastrointestinal, cardiovascular, hepatic and renal adverse events. This narrative review summarizes recent literature on the benefits and harms of paracetamol for OA pain. Data on long-term paracetamol safety are derived largely from observational evidence, and are difficult to interpret given the potential biases of such data. Nonetheless, a considerable degree of toxicity is associated with paracetamol use among the general population, especially at the upper end of standard analgesic doses. Paracetamol is linked to liver function abnormalities and there is evidence for liver failure associated with non-intentional paracetamol overdose. Safety data for paracetamol use in the older population (aged >65 years) are sparse; however, there is some evidence that frail elderly people may have impaired paracetamol clearance. Given that the analgesic benefit of paracetamol in OA joint pain is uncertain and potential safety issues have been raised, more careful consideration of its use is required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent reviews reinforced concerns regarding chronic renal dysfunction, cardiovascular risk, and adverse outcomes associated with sustained exposure, while emphasizing the limitations inherent to observational data and the possibility of residual confounding [ 21 , 42 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The evidence on long-term harm is largely observational and therefore vulnerable to confounding by indication and channeling bias, so that the reported dose-response associations remain suggestive rather than firmly causal in the absence of long-duration randomized data [ 15 , 21 ].”
From Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management (2026) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
da Costa, B. R., Reichenbach, S., Keller, N., Nartey, L., Wandel, S., Jüni, P., & Trelle, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31744-0 · Cited by 522
Retractedda Costa, B. R., Reichenbach, S., Keller, N., Nartey, L., Wandel, S., Jüni, P., & Trelle, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30002-2 · Cited by 418 · cited 1×
“In a 2017 network meta-analysis of analgesic medications for the management of pain in knee and hip OA, the authors concluded, on the basis of the available data, that there is no role for single-agent paracetamol in the treatment of OA patients irrespective of dose [21].”
BackgroundRetractedVos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291 · cited 1×
“OA is an increasingly common disease given its associations with aging and a growing obese/overweight population, with symptomatic knee OA affecting more than 250 million older people (>50 years) worldwide [3].”
BackgroundBurden of major musculoskeletal conditions.
(2003) · Europe PMC (PubMed Central) · Cited by 3,521
OARSI guidelines for the non-surgical management of knee osteoarthritis
McAlindon, T. E., Bannuru, R. R., Sullivan, M. C., Arden, N. K., Berenbaum, F., Bierma-Zeinstra, S. M., Hawker, G. A., Henrotin, Y., Hunter, D. J., Kawaguchi, H., et al. (2014) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2014.01.003 · Cited by 3,110
Self-citationHochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., Towheed, T., Welch, V., Wells, G., & Tugwell, P. (2012) · Arthritis Care & Research · doi:10.1002/acr.21596 · Cited by 3,068
OARSI recommendations for the management of hip and knee osteoarthritis
Zhang, W., Nuki, G., Moskowitz, R. W., Abramson, S., Altman, R. D., Arden, N. K., Bierma-Zeinstra, S., Brandt, K. D., Croft, P., Doherty, M., et al. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.01.013 · Cited by 1,700
Self-citationMachado, G. C., Maher, C. G., Ferreira, P. H., Pinheiro, M. B., Lin, C.-W. C., Day, R. O., McLachlan, A. J., & Ferreira, M. L. (2015) · BMJ · doi:10.1136/bmj.h1225 · Cited by 580
Acetaminophen for osteoarthritis
Towheed, T., Maxwell, L., Judd, M., Catton, M., Hochberg, M. C., & Wells, G. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004257.pub2 · Cited by 563
Bruyère, O., Cooper, C., Pelletier, J.-P., Branco, J., Luisa Brandi, M., Guillemin, F., Hochberg, M. C., Kanis, J. A., Kvien, T. K., Martel-Pelletier, J., et al. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.05.014 · Cited by 515
Self-citationParacetamol: not as safe as we thought? A systematic literature review of observational studies
Roberts, E., Delgado Nunes, V., Buckner, S., Latchem, S., Constanti, M., Miller, P., Doherty, M., Zhang, W., Birrell, F., Porcheret, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206914 · Cited by 412
Self-citation(2014) · PubMed · Cited by 390
Gregori, D., Giacovelli, G., Minto, C., Barbetta, B., Gualtieri, F., Azzolina, D., Vaghi, P., & Rovati, L. C. (2018) · JAMA · doi:10.1001/jama.2018.19319 · Cited by 337
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595793 · Cited by 319
James Williams, H., Ward, J. R., Egger, M. J., Neuner, R., Brooks, R. H., Clegg, D. O., Field, E. H., Skosey, J. L., Alarcón, G. S., Willkens, R. F., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360904 · Cited by 262 · cited 2×
“A recent meta-analysis focusing on the long-term efficacy of pharmacotherapy for OA [22], identified only one RCT of > 12 months’ duration that included paracetamol (650 mg, four times daily) in comparison with naproxen (375 mg, twice daily) [23].”
BackgroundO'Neil, C. K., Hanlon, J. T., & Marcum, Z. A. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.09.004 · Cited by 261
A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States
Blieden, M., Paramore, L. C., Shah, D., & Ben-Joseph, R. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.904744 · Cited by 261
García Rodríguez, L. A., & Hernández-Díaz, S. (2001) · Arthritis Research & Therapy · doi:10.1186/ar146 · Cited by 236
McLachlan, A. J., Bath, S., Naganathan, V., Hilmer, S. N., Le Couteur, D. G., Gibson, S. J., & Blyth, F. M. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03847.x · Cited by 227
Acetaminophen: Dose-Dependent Drug Hepatotoxicity and Acute Liver Failure in Patients
Jaeschke, H. (2015) · Digestive Diseases · doi:10.1159/000374090 · Cited by 221
Kingsbury, S. R., Gross, H. J., Isherwood, G., & Conaghan, P. G. (2014) · Rheumatology · doi:10.1093/rheumatology/ket463 · Cited by 198
Self-citationCraig, D. G. N., Bates, C. M., Davidson, J. S., Martin, K. G., Hayes, P. C., & Simpson, K. J. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04067.x · Cited by 168 · cited 2×
“The study found that ‘staggered’ paracetamol overdoses (repeated supratherapeutic ingestions of paracetamol), frequently taken to relieve pain, are strongly associated with reduced survival compared with single time-point overdose [41].”
BackgroundLifetime Nonnarcotic Analgesic Use and Decline in Renal Function in Women
Curhan, G. C., Knight, E. L., Rosner, B., Hankinson, S. E., & Stampfer, M. J. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1519 · Cited by 166
Conaghan, P. G., Peloso, P. M. J., Everett, S. V., Rajagopalan, S., Black, C. M., Mavros, P., Arden, N., Phillips, C. J., Rannou, F., van de Laar, M. A. F. J., et al. (2014) · Rheumatology · doi:10.1093/rheumatology/keu332 · Cited by 154 · cited 1×
“In an observational study of real-world therapies for OA, after ≥ 2 weeks of physician-prescribed treatment, more than half of patients with knee OA reported inadequate pain relief defined as moderate to severe pain [16].”
BackgroundSelf-citationThe Association of Age and Frailty with Paracetamol Conjugation in Man
WYNNE, H. A., COPE, L. H., HERD, B., RAWLINS, M. D., JAMES, O. F. W., & WOODHOUSE, K. W. (1990) · Age and Ageing · doi:10.1093/ageing/19.6.419 · Cited by 149
The PAIN Study: Paracetamol, Aspirin and Ibuprofen New Tolerability Study
Moore, N. D., Ganse, E. H. V., Leparc, J.-M., Wall, R., Schneid, H., Farhan, M., Verri??re, F., & Pelen, F. O. (1999) · Clinical Drug Investigation · doi:10.2165/00044011-199918020-00001 · Cited by 147
Rahme, E., Barkun, A., Nedjar, H., Gaugris, S., & Watson, D. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01811.x · Cited by 138 · cited 1×
“The rates of hospitalization for GI disorders (ulceration, perforation, or bleeding in the upper or lower GI tract) among elderly patients (≥ 65 years) taking traditional NSAIDs, or the combination of a traditional NSAID and paracetamol with and without a proton pump inhibitor (PPI) versus those taking paracetamol alo…”
MethodRodriguez, L. A. G. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwh005 · Cited by 137
Kluzek, S., Sanchez-Santos, M. T., Leyland, K. M., Judge, A., Spector, T. D., Hart, D., Cooper, C. C., Newton, J. L., & Arden, N. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208056 · Cited by 126
Self-citationLiver transplant associated with paracetamol overdose: results from the seven‐country SALT study
Gulmez, S. E., Larrey, D., Pageaux, G., Bernuau, J., Bissoli, F., Horsmans, Y., Thorburn, D., McCormick, P. A., Stricker, B., Toussi, M., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12635 · Cited by 99
Kingsbury, S. R., Hensor, E. M. A., Walsh, C. A., Hochberg, M. C., & Conaghan, P. G. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4286 · Cited by 94
Self-citationBoureau, F., Schneid, H., Zeghari, N., Wall, R., & Bourgeois, P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.011403 · Cited by 91
Reporting of age data in clinical trials of arthritis. Deficiencies and solutions
Rochon, P. A. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.2.243 · Cited by 79
de Abajo, F. J., Gil, M., García-Poza, P., Bryant, V., Oliva, B., Timoner, J., & García‐Rodríguez, L. A. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3617 · Cited by 75
García-Poza, P., de Abajo, F. J., Gil, M., Chacón, A., Bryant, V., & García‐Rodríguez, L. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12855 · Cited by 59
Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes
De Vries, F., Setakis, E., & Van Staa, T. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03705.x · Cited by 57
Reporting of Age Data in Clinical Trials of Arthritis: Deficiencies and Solutions
Rochon, P. A. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410020091008 · Cited by 55
Rampal, P., Moore, N. D., Ganse, E. H. V., Parc, J.-M. L., Wall, R., Schneid, H., & Verrière, F. (2002) · Journal of International Medical Research · doi:10.1177/147323000203000311 · Cited by 39
A population-based cohort study of mortality among adults prescribed paracetamol in Denmark
Lipworth, L. P., Friis, S., Mellemkjær, L., Signorello, L. B., Johnsen, S. P., Nielsen, G. L., McLaughlin, J. K., Blot, W. J., & Olsen, J. H. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(03)00152-5 · Cited by 29
Gualtierotti, R., Zoppi, A., Mugellini, A., Derosa, G., D’Angelo, A., & Fogari, R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.816286 · Cited by 25
Raja, R., Dube, B., Hensor, E. M. A., Hogg, S. F., Conaghan, P. G., & Kingsbury, S. R. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1049-0 · Cited by 24
Self-citationChevé, H., Marinthe, A.-C., Lelong‐Boulouard, V., Lescure, P., & Guillaumé, C. (2018) · Gériatrie et Psychologie Neuropsychiatrie du Viellissement · doi:10.1684/pnv.2017.0709 · Cited by 1
Cited by
Bruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., Al-Daghri, N. M., Herrero-Beaumont, G., Martel-Pelletier, J., Pelletier, J.-P., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.008 · Cited by 695
“use, due to increasing evidence of gastrointestinal (GI), cardiovascular (CV), hepatic and renal adverse events (AEs) [48].”
BackgroundSelf-citationda Costa, B. R., Pereira, T. V., Saadat, P., Rudnicki, M., Iskander, S. M., Bodmer, N. S., Bobos, P., Gao, L., Kiyomoto, H. D., Montezuma, T., et al. (2021) · BMJ · doi:10.1136/bmj.n2321 · Cited by 377
“11 33 34 59 Our analyses indicate that the small benefits of opioids or paracetamol might be outweighed by potential harms, regardless of dose.”
BackgroundParacetamol: A Review of Guideline Recommendations
Freo, U., Ruocco, C., Valerio, A., Scagnol, I., & Nisoli, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153420 · Cited by 208
The advances in nanomedicine for bone and cartilage repair
Qiao, K., Xu, L., Tang, J., Wang, Q., Lim, K. S., Hooper, G. J., Woodfield, T. B. F., Liu, G., Tian, K., Zhang, W., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01342-8 · Cited by 138
“Due to the demographic shift to an aging and obese society, the risk of cartilage [4, 5] and bone [6] damage in the population has increased significantly.”
BackgroundPrimorac, D., Molnar, V., Matišić, V., Hudetz, D., Jeleč, Ž., Rod, E., Čukelj, F., Vidović, D., Vrdoljak, T., Dobričić, B., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14030205 · Cited by 142
“In some patients, higher doses or prolonged use of acetaminophen can be hepatotoxic [12].”
Background
Metadata
- Authors
- Conaghan, P. G., Arden, N., Avouac, B., Migliore, A., & Rizzoli, R.
- Affiliations
- University of Leeds (GB)
- Southampton General Hospital (GB)
- University of Liège (BE)
- Fatebenefratelli Hospital (IT)
- University of Geneva (CH)
- Corresponding author
- Conaghan, Philip G.
- Venue
- Drugs & Aging
- Published
- 2019-04
- Volume
- 36
- Issue
- S1
- Pages
- 7-14
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- PMC
- PMC6509082
- OpenAlex
- W2944358359
- Cited by
- 101
- References
- 42
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 13 · 2023: 10 · 2022: 19 · 2021: 21 · 2020: 11 · 2019: 5
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- Locations
- Drugs & Aging (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by-nc)
- Funders
- National Institute for Health and Care Research
- Leeds Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- paracetamol, osteoarthritis, drug safety, analgesia, adverse drug reactions, hepatotoxicity, liver failure, acetaminophen overdose, gastrointestinal toxicity, cardiotoxicity, nephrotoxicity, elderly patients, frail elderly, joint pain
- MeSH terms
- Acetaminophen, Aged, Dose-Response Relationship, Drug, Humans, Osteoarthritis, Analgesics, Non-Narcotic, Arthralgia, Chemical and Drug Induced Liver Injury, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.